At $215, Moderna Stock Already Prices In A Comeback
Today’s big story: Could Nvidia Stock Fall 50%? Follow The Cash
Our Nov 16 piece, How Much Could Moderna Stock Give Back?, found that Moderna (MRNA) stock had returned 736.3% over the twelve months to Nov 13, against 11.7% for the S&P 500. The next question is the long one: where could the stock be in five years?
The short answer: a higher price in 2031 needs Moderna to beat a forecast that already assumes a big comeback. At Monday’s close of $215.27, the stock trades at about 49.8 times the average analyst estimate for 2030 earnings of $4.32 a share. Even the most optimistic 2030 estimate, $6.40, leaves it at 33.7 times. No analyst estimate reaches 2031, so 2030 is the furthest yardstick we have.
Here is the number that frames it. Five years ago, on Nov 16, 2021, Moderna closed at $234.28. Monday’s close is 8.1% below that, while the S&P 500 ETF SPY returned 68.6% over the same five years. The stock has already lived through one five-year round trip. The question is what the next one has to deliver.

What The 2030 Estimates Already Assume
Moderna’s revenue was $1.922 billion in 2025, 89.8% below its 2022 level of $18.875 billion. Analysts’ average 2030 revenue estimate is $8.22 billion. Getting there means revenue about 4.3 times 2025’s, or growth of about 33.7% a year for five years. That is the base case, not the bull case.
Profits come late in that path. The average estimate has Moderna losing money through 2028 and turning profitable only in 2029, at $0.84 a share, before $4.32 in 2030. At a market value of about $87.0 billion, the company is valued at 10.6 times that 2030 revenue average.
To see what that means for the price, we ran a simple illustration, not a forecast. If the market paid 20 times 2030 earnings, the average estimate would put the stock at $86.37, about 59.9% below Monday’s close, and the highest estimate at $127.90, about 40.6% below. Twenty times is an assumption we picked to show the scale; a higher multiple changes the result. The point is that today’s price already leans on numbers near the top of the range.
| 2030 yardstick | Estimate | Price multiple at $215.27 |
|---|---|---|
| Average EPS | $4.32 | 49.8x |
| Highest EPS | $6.40 | 33.7x |
| Average revenue | $8.22 billion | 10.6x sales |
The Case That The Estimates Are Too Low
The bull side has real facts behind it. Moderna earned $162 million in the third quarter, or $0.38 a share, against a loss of $0.51 a share a year earlier. CFO James Mock said revenue was $1.3 billion, up 29%, mostly from higher COVID sales. On Nov 6 the company raised its 2026 revenue growth outlook to a range with a midpoint of 20%, above its earlier outlook.
The pipeline is the bigger lever. Merck and Moderna said on Aug 19 that the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its main goals in resected stage IIB-IV melanoma. Moderna lists the filing for approval of that drug among its next key milestones, along with a kidney cancer readout and a registrational readout in propionic acidemia. Its flu shot mFLUSIVA became its fifth approved product and the first mRNA flu vaccine on the market. We covered what Moderna is building beyond COVID earlier this month. If those products push revenue toward the top 2030 estimate of $11.26 billion, the multiples above shrink fast.
The balance sheet buys time. Moderna held about $8.0 billion of cash and investments on Sep 30, and it expects $8.1 billion to $8.3 billion at year-end.
The Case That They Are Not
The cash is not free. Free cash flow was -$2.935 billion in the first nine months of 2026, and total debt rose to $4.229 billion on Sep 30 from $1.287 billion on Jun 30, after a $3 billion convertible note. For the nine months Moderna lost $1.963 billion on revenue of $1.844 billion.
The price has also moved fast in both directions. The stock is up 769.1% from Nov 14, 2025 to Monday, even after falling 20.0% from its Nov 9 close of $269.00 in the last five sessions. On Monday alone it fell 3.6% while the S&P 500 fell 1.9%. It remains 55.6% below its record close of $484.47 in August 2021. A stock that swings this much can reach a five-year mark far from where its business ends up.
How An Owner Might Use This
We think the useful way to hold a five-year view on Moderna is as a test, not a target. The dates that test it are near: the melanoma filing and the two readouts, which we mapped in which dates could move Moderna stock most. If the next full-year results show revenue tracking toward the 2030 average, the bull case gains ground; if growth stalls near the 2026 guide, the 49.8 times multiple looks harder to defend. For a different shape of five-year question, see Could Your Dell Shares Be Worth $906 Or $114?.
Our conclusion: at $215.27, Moderna’s price already counts on a large rebound, so the five-year upside depends on beating estimates that are generous to begin with. After a run this steep, the gains are real but the stock may now be a bigger slice of a portfolio than any one bet should be. Deciding ahead of time how much to keep, and when to sell the rest, beats letting the next swing decide for you.
Too Much Riding On One Stock?
If Moderna is a big part of your wealth, so are its risk and its tax bill. What’s your exit plan? Our partner advisory firm offers a free 30-minute strategy review covering a floor under losses and a lower-tax way out.
For questions about this article or underlying research, email help@trefis.com.